Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.